Magnesium sulfate, solution for injection, 250 mg/ml, 5 ml each; Papaverine, solution for injection, 20 mg/ml, 2 ml each; Sodium chloride, solution for injection, 9 mg/ml, 5 ml each; Furosemide, solution for injection, 10 mg/ml, 2 ml each; Chloropyramine, solution for injection, 20 mg/ml, 1 ml each; Diphenhydramine, solution for injection, 10 mg/ml, 1 ml each; Metamizole sodium, solution for injection, 500 mg/ml, 2 ml; Prednisone, solution for injection, 30 mg/ml, 1 ml each; Theophylline so
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Classification according to ATX: D08AC02, INN: Chlorhexidine, Release form: Solution for external use, Dose of active substance: 0.05%, Volume: 100 ml, Packaging type: Vial; Ondansetron solution for injection 2 mg/ml in 4 ml; Classification according to INN: Acetylsalicylic acid, Classification according to ATX: B01AC06, Release form, Dose of active substance: 75 mg, Type of packaging: Blister, Vial, Strip; Classification according to ATC: N05CB02, Classification according to INN: Barbiturates in combination with other drugs, Release form: Oral drops, Volume: 25 milliliters, Packaging type: Vial, Ethyl ether of alpha-bromosovaleric acid: 20 mg, Phenobarbital: 18.26 mg, Peppermint oil: 1.42 mg